The PE Ratio as of November 2024 (TTM) for Dyadic International, Inc. (DYAI) is -8.39

According to Dyadic International, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -8.39. This represents a change of -38.72% compared to the average of -13.69 of the last 4 quarters.

Dyadic International, Inc. (DYAI) Historical PE Ratio (quarterly & annually)

How has DYAI PE Ratio performed in the past?

The mean historical PE Ratio of Dyadic International, Inc. over the last ten years is -10.23. The current -8.39 PE Ratio has changed 8.10% with respect to the historical average. Over the past ten years (40 quarters), DYAI's PE Ratio was at its highest in in the March 2023 quarter at 93.01. The PE Ratio was at its lowest in in the September 2024 quarter at -37.70.

Dyadic International, Inc. (DYAI) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Dyadic International, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Dyadic International, Inc. (DYAI) Average PE Ratio

How has DYAI PE Ratio performed in the past?

The current PE Ratio of Dyadic International, Inc. (DYAI) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Dyadic International, Inc. (DYAI) PE Ratio vs. Peers

How is DYAI’s PE Ratio compared to its peers?

Dyadic International, Inc.’s PE Ratio is less than Werewolf Therapeutics, Inc. (-1.34), greater than Edgewise Therapeutics, Inc. (-24.30), less than Decibel Therapeutics, Inc. (-1.95), less than Celcuity Inc. (-6.01), less than C4 Therapeutics, Inc. (-2.80), less than Anebulo Pharmaceuticals, Inc. (-4.78), less than PMV Pharmaceuticals, Inc. (-1.61), less than AN2 Therapeutics, Inc. (-0.66), less than Eliem Therapeutics, Inc. (-2.42), less than HCW Biologics Inc. (-0.78), less than Molecular Partners AG (-2.50), less than MediciNova, Inc. (-0.04), greater than Champions Oncology, Inc. (-18.21), greater than Cyteir Therapeutics, Inc. (-9.12), less than Forte Biosciences, Inc. (-0.86), greater than DiaMedica Therapeutics Inc. (-9.26), less than Kineta, Inc. (-0.36), less than Kintara Therapeutics, Inc. (-0.07),

Build a custom stock screener for Dyadic International, Inc. (DYAI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Dyadic International, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Dyadic International, Inc. (DYAI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Dyadic International, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.